Tag: drug discovery

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

The study showed that orelabrutinib was safe and well tolerated in participants with SLE.

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

BOSTON, June 4, 2026 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, allosteric small molecules that target...

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

TAIPEI, June 4, 2026 /PRNewswire/ -- Compal Electronics (Compal; TWSE: 2324) showcases its landmark achievements in Quantum Technology and Advanced Artificial Intelligence (AI) at COMPUTEX...

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

InnoCare's novel BCL2i mesutoclax in MDS and AML was released at 2026 ASCO as an oral presentation, demonstrating outstanding efficacy and safety.

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Tokyo, Japan and Cambridge, UK, 2 June 2026 – Nxera Pharma Co., Ltd. (“Nxera” or the “Company”)　 announces that the Ministry of Food and Drug Safety (MFDS) of the Republic of Korea has granted Orphan Drug Designation (ODD) and Global Innovative Products on Fast Track (GIFT) designation to vamorolone for the treatment of Duchenne muscular dystrophy (DMD). The Company plans to submit a Marketing Authorization Application (MAA) for vamorolone in South Korea during 2026.

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

All dollar amounts reflected in Canadian dollars unless otherwise stated.

Phenomenex Launches Endrix Long Life Columns, Redefining Column Durability and Method Reliability

Redefined Column Durability and Method ReliabilityTORRANCE, Calif., June 1, 2026 /PRNewswire/ -- Phenomenex Inc., a Danaher Company and a global leader in the research...

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

Zifo accelerates antibody engineering and therapeutics development with launch of AI-Powered Protein Models on Snowflake CAMBRIDGE, Mass., CAMBRIDGE, England and CHENNAI, India, Aug. 14,...

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

- The combination of ASC47 low dose with tirzepatide in diet-induced obese (DIO) mice resulted in an 87% greater reduction in...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

60 Global Rising Stars from 1,200 Universities will Converge in Singapore for SMU’s 12th Lee Kuan Yew Competition Grand Finals

60 finalists for SG60 milestone edition selected by an international panel of judges and visionary partnersFocus on empowering Urban Solutions and Sustainability to solve...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

This field is for validation purposes and should be left unchanged.

HomeTagsDrug discovery

Quantinuum Announces Closing of Upsized Initial Public Offering

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Food Safety Testing Market Expected to Reach $44.1 Billion by 2033, at a CAGR of 7% : Allied Market Research

Tag: drug discovery

Phase IIb Study Results of InnoCare’s Orelabrutinib in Patients with SLE Presented at 2026 EULAR

HotSpot Therapeutics Presents Preclinical Data from Small Molecule IRF5 Inhibitor Program at EULAR 2026

【COMPUTEX 2026】Compal Integrates Quantum Technology and AI – Partnering with Top Universities and Pharmaceutical Firms to Build a Biotech AI Platform

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare’s Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

Nxera’s Vamorolone Granted Key Regulatory Designations Supporting Faster Access for Duchenne Muscular Dystrophy Patients in South Korea

Rakovina Therapeutics Announces Q1 2026 Financial Results and Provides Corporate Update

Phenomenex Launches Endrix Long Life Columns, Redefining Column Durability and Method Reliability

Zifo Launches AI Antibody Engineering App on Snowflake Marketplace to Accelerate Biologics and Drug Discovery

Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, Demonstrated Greater Efficacy with Tirzepatide than Semaglutide in a Preclinical Model

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

Fosun Pharma’s Small Molecule Innovative Drug XH-S004 Achieves Overseas Licensing for a Potential Total of $645 Million

REPEAT – Tevogen CEO Affirms Strong Growth, Capital Position, and AI Expansion in Letter to Stockholders

Idorsia publishes interim results of repurchase offer for its 2025 and 2028 convertible bonds

60 Global Rising Stars from 1,200 Universities will Converge in Singapore for SMU’s 12th Lee Kuan Yew Competition Grand Finals

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us